The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Kjeldsen SE, Brunström M, Thomopoulos C, Carlberg B, Kreutz R, Mancia G(2022) Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes Lancet Diabetes Endocrinol, 10(12), 840 DOI 10.1016/S2213-8587(22)00312-6, PubMed 36427519
Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH(2022) Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression J Immunol, 209(10), 2042-2053 DOI 10.4049/jimmunol.2200144, PubMed 36426942
Ghiasvand R, Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Karlstad Ø, Juzeniene A, Larsen IK, Green AC, Veierød MB, Robsahm TE(2022) Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study Int J Epidemiol(in press) DOI 10.1093/ije/dyac223, PubMed 36413027